<DOC>
	<DOCNO>NCT02661503</DOCNO>
	<brief_summary>Primary objective trial demonstrate non-inferior efficacy six cycle BrECADD compare six cycle escalate BEACOPP , follow radiotherapy PET-positive residual lesion â‰¥2.5 cm , term progression free survival ( efficacy objective ) . If non-inferior efficacy show , co-primary objective demonstrate reduce toxicity BrECADD treatment compare escalated BEACOPP treatment measure treatment relate morbidity ( TRMorbidity objective ) .</brief_summary>
	<brief_title>HD21 Advanced Stages</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven classical Hodgkin lymphoma First diagnosis , previous treatment , 18 60 year age Stage IIB large mediastinal mass and/or extranodal lesion , stage III IV Composite lymphoma nodular lymphocytepredominant Hodgkin lymphoma Previous malignancy ( exception : basalioma , carcinoma situ cervix uterus , completely resect melanoma TNMpT1 ) Prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>